ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
June 28, 2021Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT -
Takeda enters $1.04bn deal with Arrowhead Pharmaceuticals
October 16, 2020Takeda has entered a collaboration and licensing agreement with Arrowhead Pharmaceuticals to develop an investigational drug, ARO-AAT, for the treatment of alpha-1 antitrypsin-associated liver disease (AATLD).
Pharma Sources Insight January 2025
